13F filerCIK 1061768 ↗
Baupost Group
You are looking at Q2 2019. See the latest, Q3 2026 →
Reported value
$11.05B
−7.2% on the quarter before
Positions
32
1 new, 4 sold out
Top 10
70.2%
of the value
Est. gain
+$52.5M
on stocks held all quarter
Est. return
+0.5%
on those stocks since Q1 2019
Positions as of Jun 30, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2019. Striped tiles are options.
Largest buys
Since Q1 2019, sized at quarter-end prices.
- Bristol Myers Squibb Co~$408.1MAdded, 1.6% → 5.3% of the portfolio+9,000,000 shares
- Xpo Logistics Inc~$86.7MNew, 0.0% → 0.8% of the portfolio+1,500,000 shares
- Liberty Global Plc~$75.5MAdded, 8.0% → 10.1% of the portfolio+2,844,679 shares
- Cbs Corp New~$72.8MAdded, 3.4% → 4.5% of the portfolio+1,457,984 shares
- Liberty Global Plc~$67.0MAdded, 1.0% → 1.8% of the portfolio+2,483,500 shares
- Nexstar Media Group Inc~$40.2MAdded, 0.9% → 1.3% of the portfolio+397,755 shares
- Translate Bio Inc~$29.1MAdded, 0.5% → 1.0% of the portfolio+2,352,941 shares
- Atara Biotherapeutics Inc~$12.5MAdded, 2.1% → 1.3% of the portfolio+619,481 shares
- Trilogy Metals Inc New~$1.7MAdded, 0.3% → 0.4% of the portfolio+590,610 shares
Largest sells
Since Q1 2019, sized at quarter-end prices.
- Celgene Corp~$377.4MSold out, 3.2% → 0.0% of the portfolio−4,000,000 shares
- Pioneer Nat Res Co~$304.8MSold out, 2.6% → 0.0% of the portfolio−2,001,814 shares
- Ebay Inc~$203.0MCut, 9.1% → 8.6% of the portfolio−5,140,000 shares
- Allergan Plc~$182.5MCut, 5.9% → 5.6% of the portfolio−1,090,146 shares
- Synchrony Finl~$173.4MCut, 3.8% → 2.9% of the portfolio−5,000,000 shares
- Cheniere Energy Inc~$133.1MCut, 7.2% → 6.6% of the portfolio−1,944,173 shares
- Qorvo~$127.1MCut, 6.4% → 5.2% of the portfolio−1,907,901 shares
- Sinclair Broadcast Group Inc~$126.5MCut, 0.9% → 0.3% of the portfolio−2,358,673 shares
- Walt Disney Company (The)~$44.3MSold out, 0.4% → 0.0% of the portfolio−399,151 shares
- Mckesson Corp~$29.6MCut, 2.8% → 3.2% of the portfolio−220,000 shares
Holdings
As of Jun 30, 2019; changes in shares since Mar 31, 2019.
| Holding | Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Liberty Global PlcSHS CL C · shares +7.3% · price +9.6% | 10.1% | $1.11B | +$90.7M | ||||||
| Viasat IncCOM · shares 0% · price +4.3% | 10.0% | $1.11B | +$45.6M | ||||||
| Fox CorpCL A COM · shares 0% · price −0.2% | 9.1% | $1.00B | −$1.9M | ||||||
| Ebay IncCOM · shares −18% · price +6.4% | 8.6% | $953.8M | +$57.0M | ||||||
| Cheniere Energy IncCOM NEW · shares −15% · price +0.1% | 6.6% | $730.6M | +$960,738 | ||||||
| Allergan PlcSHS · shares −23% · price +14.4% | 5.6% | $616.1M | +$77.3M | ||||||
| Bristol Myers Squibb CoCOM · shares +225% · price −4.9% | 5.3% | $589.5M | −$9.4M | ||||||
| QorvoCOM · shares −18% · price −7.1% | 5.2% | $578.3M | −$44.4M | ||||||
| Pg&E CorpCOM · shares 0% · price +28.8% | 5.1% | $561.5M | +$125.4M | ||||||
| Cbs Corp NewCL B · shares +17% · price +5.0% | 4.5% | $499.0M | +$20.2M | ||||||
| Mckesson CorpCOM · shares −7.8% · price +14.8% | 3.2% | $348.7M | +$45.0M | ||||||
| Synchrony FinlCOM · shares −35% · price +8.7% | 2.9% | $321.1M | +$25.7M | ||||||
| TeslaNOTE 2.375% 3/1 · shares 0% · price −10.0% | 2.7% | $295.5M | — | ||||||
| Colony Cap Inc NewCL A COM · shares 0% · price −6.0% | 2.2% | $248.4M | −$15.9M | ||||||
| Univar IncCOM · shares 0% · price −0.5% | 1.9% | $209.4M | −$1.1M | ||||||
| Fox CorpCL B COM · shares 0% · price +1.8% | 1.9% | $207.5M | +$3.7M | ||||||
| Liberty Global PlcSHS CL A · shares +50% · price +8.3% | 1.8% | $200.8M | +$10.3M | ||||||
| Amerisourcebergen CorpCOM · shares −7.9% · price +7.2% | 1.7% | $188.8M | +$12.7M | ||||||
| Takeda Pharmaceutical Co LtdSPONSORED ADS · shares −12% · price −13.1% | 1.5% | $167.1M | −$25.2M | ||||||
| Antero Res CorpCOM · shares 0% · price −37.4% | 1.4% | $158.1M | −$94.3M | ||||||
| Theravance Biopharma IncCOM · shares 0% · price −28.0% | 1.4% | $152.0M | −$59.0M | ||||||
| Nexstar Media Group IncCL A · shares +40% · price −6.8% | 1.3% | $141.2M | −$7.4M | ||||||
| Atara Biotherapeutics IncCOM · shares +9.7% · price −49.4% | 1.3% | $140.8M | −$125.3M | ||||||
| Akebia Therapeutics IncCOM · shares 0% · price −40.9% | 1.1% | $118.4M | −$82.0M | ||||||
| Translate Bio IncCOM · shares +36% · price +25.5% | 0.99% | $109.4M | +$16.3M | ||||||
| Total 32 positions | 100% | $11.05B | +$52.5M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2019 to Q2 2019: 29 stocks held throughout, up $52.5M (+0.5%).
- Pg&E Corp+$125.4M+29%
- Liberty Global Plc+$90.7M+10%
- Allergan Plc+$77.3M+14%
- Ebay Inc+$57.0M+6%
- Viasat Inc+$45.6M+4%
- Qorvo−$44.4M−7%
- Theravance Biopharma Inc−$59.0M−28%
- Akebia Therapeutics Inc−$82.0M−41%
- Antero Res Corp−$94.3M−37%
- Atara Biotherapeutics Inc−$125.3M−49%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | $5.05B−7% | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | $5.42B+6% | SEC ↗ |
| Q1 2026 | May 14, 2026 | $5.12B−3% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $5.28B+10% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $4.79B+16% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $4.13B+18% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $3.50B+2% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $3.43B−2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $3.52B−3% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $3.63B−0% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $3.65B−20% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $4.59B−12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $5.21B−7% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $5.61B−4% | SEC ↗ |
| Q1 2023 | May 12, 2023 | $5.85B−5% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $6.13B+6% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $5.79B−14% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $6.77B−27% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $9.30B−8% | SEC ↗ |
| Q4 2021 | Feb 11, 2022 | $10.13B−7% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $10.88B−12% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $12.33B−2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $12.56B+16% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $10.84B+17% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $9.25B+15% | SEC ↗ |
| Q2 2020 | Aug 13, 2020 | $8.01B+18% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $6.77B−25% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $9.06B+3% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $8.83B−20% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $11.05B−7% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $11.90B+3% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 | $11.52B−12% | SEC ↗ |
| Q3 2018 | Nov 15, 2018 (amended) | $13.06B+14% | SEC ↗ |
| Q2 2018 | Aug 13, 2018 | $11.44B+10% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $10.37B+3% | SEC ↗ |
| Q4 2017 | Feb 13, 2018 | $10.11B+26% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $8.02B−8% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $8.75B+3% | SEC ↗ |
| Q1 2017 | May 25, 2017 (amended) | $8.49B+11% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $7.67B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $7.04B−4% | SEC ↗ |
| Q2 2016 | Aug 12, 2016 | $7.37B+6% | SEC ↗ |
| Q1 2016 | May 13, 2016 | $6.92B | SEC ↗ |